Ypsomed increases auto-injector production in Germany

October 17, 2024 By Sean Whooley

The Burgdorf, Switzerland-based company said its expansion enables an increase in production capacity to meet growing global demand. CEO Simon Michel also said the company plans to further expand the plant in the coming years.

Ypsomed invested approximately $25.4 million (22 million CHF) in the new production hall, called Hall D. It extends upon the existing Halls A-C with 30 state-of-the-art plastic injection molding machines and three assembly lines. The company says it can produce an additional 100 million auto-injectors per year in Schwerin.

According to a news release, the company plans to begin construction on “Schwerin II” in January 2025. The first phase expands the production area by 25,000 square meters. It also adds a fully automated high-bay warehouse, an administration building and a central technical building.

Ypsomed’s second construction phase, expected to kick off in 2027 or 2028, adds a further 17,000 square meters. This could increase the company’s production capacity by 400 million to 500 million pens and autoinjectors per year. The company said its investment sum amounts to almost half a billion Swiss francs, or about $578 million.

Initially, the company expects to create 85 new jobs and apprenticeships in Schwerin with the newly opened production hall. It anticipates about 350 new jobs created through the first phase of the Schwerin II project. The new expansions also feature sustainable aspects, such as photovoltaic systems on the roofing and a planned wind turbine. Ypsomed also plans to make Hall D a CO2-neutral building.

“The expansion of our Schwerin site is an important step in our growth strategy, which will enable us to increase our production capacity and expand further in the coming years,” said Michel.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: Ypsomed